Abstract:270 Background: Radiotracers used in prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging have high specificity for the detection of prostate cancer (PCa), and PSMA PET/CT imaging has seen increased use in the management of localized PCa. However, the diagnostic capability of PSMA PET can be limited by intense uptake in the ureters, bladder, and urethra due to physiologic urinary excretion. Specifically, radiotracer activity in the prostatic urethra can be misinterpreted as a midline intraprostatic lesion if not carefully evaluated with morphologic imaging. This study aimed to elucidate the correlation between positive 18 F-DCFPyL activity in the midline prostate with hyperintense signal on T2-weighted MRI (T2W MRI) within the prostatic urethra as an indication of retained urine. Methods: Ninety-seven patients received both 18 F-DCFPyL PSMA PET/CT and 3 Tesla prostate MRI post-void imaging for localized, high-risk PCa. Patients with prior prostate treatment (i.e., surgery, androgen deprivation therapy, or radiotherapy) or poor prostatic urethra visualization (i.e., PCa involving the whole gland, Foley catheter in situ) were excluded, resulting in a final cohort of 84 patients. Radiotracer activity in the midline region of the prostate was prospectively evaluated by two nuclear medicine physicians during PET/CT read outs. Post-void T2W MRI scans were retrospectively evaluated for the presence of residual urine noted as hyperintensity within the prostatic urethral lumen by one genitourinary radiologist blinded to PET/CT evaluations. The corresponding prostatic urethra diameters were measured on both axial and sagittal T2W MRI. Fisher’s exact test and Mann-Whitney U tests were used to compare MRI and PET/CT findings. Results: In 84 patients, midline activity on PSMA PET imaging was documented in 16 patients (the case group), whereas the remaining 68 patients without midline activity constituted the control group. In total, 75% (12/16) and 31% (21/68) of patients in the case and control groups, respectively, had urethral hyperintensity on T2W MRI (p < .01, Fisher’s exact test). In patients with a hyperintense urethral lumen at MRI, there was a significant difference in mean prostatic urethral measurements between the case and control groups in both axial (7.25 mm vs. 2.81 mm, p < .0001, Mann Whitney U) and sagittal (12.25 mm vs. 5.43 mm, p < .0001, Mann Whitney U) planes. Conclusions: Our findings suggest that PSMA uptake within the midline of the prostate is more commonly observed in patients with a prominently visible prostatic urethra at MRI, a finding that is likely associated with the stagnation of urine containing PSMA tracer. This midline uptake may be prone to misinterpretation as a potential PCa lesion on PSMA PET/CT, and the use of post-void MRIs may be useful in reducing the likelihood of false positive interpretations of PSMA PET/CT.

68Ga-PSMA PET/CT Found Lower Respiratory Tract Inflammation Due to Inhaler Use

18F-DCFPyL PSMA PET/CT Tracheobronchial Uptake in Patients with Prostate Cancer: Incidence and Etiology

Detection of Docetaxel-induced Interstitial Pneumonitis on Ga-68 PSMA PET/CT Imaging

COVID-19 pneumonia incidentally discovered on [18F]F-PSMA-1007 PET/CT scan

Contribution of 68Ga-DOTA-FAPI-04 PET/CT to Prostate Cancer Imaging

Pulmonary Tc99m-PSMA uptake in asymptomatic COVID-19 patient: incidental finding in SPECT/CT study

Intramuscular Granular Cell Tumor Detected on 68Ga-PSMA PET/CT

Evaluation of Gallium-68 prostate-specific membrane antigen, positron emission tomography/computed tomography (GA-68 PSMA PET/CT) in recurrent prostate cancer: a retrospective review of initial clinical experience at Tygerberg Hospital

PSMA PET imaging for evaluation of recurrent or persistent prostate cancer after primary prostate radiation.

Extrapleural solitary fibrous tumor evidenced by 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography study in the staging of a high-risk prostate cancer patient

Detection of benign granular cell tumor of the breast via 18F-PSMA-PET/CT in a patient with very high-risk prostate cancer: A case report

False Positive Findings of [18F]PSMA-1007 PET/CT in Patients After Radical Prostatectomy with Undetectable Serum PSA Levels

[89Zr]Zr-PSMA-617 PET/CT in a Patient with Biochemical Recurrence of Prostate Cancer and Prior Indetermined Findings on [18F]PSMA-1007 Imaging

An exploratory study of unexplained concentration of 18F-PSMA-1007 in the bladder for prostate cancer PET/CT imaging

[68Ga]PSMA-11 for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer

Imaging Characteristics and First Experience of [68Ga]THP-PSMA, a Novel Probe for Rapid Kit-Based Ga-68 Labeling and PET Imaging: Comparative Analysis with [68Ga]PSMA I&T

[68Ga]PSMA PET/CT Improves Initial Staging and Management Plan of Patients with High-Risk Prostate Cancer

Effect of urinary stagnation in the prostatic urethra on generating false-positive midline lesions on 18 F-DCFPyL PSMA PET/CT.

Distinguishing Physiological Ureter Uptake From an Involved Lymph Node in Staging Prostate-Specific Membrane Antigen (PSMA) Scans: Implications for Radiation Planning

68Ga-PSMA PET/CT targeted biopsy for the diagnosis of clinically significant prostate cancer compared with transrectal ultrasound guided biopsy: a prospective randomized single-centre study

18 F-PBR06 PET/CT Imaging of Inflammation and Differentiation of Lung Cancer in Mice